<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01930422</url>
  </required_header>
  <id_info>
    <org_study_id>12 392 02</org_study_id>
    <secondary_id>AOL 2012</secondary_id>
    <nct_id>NCT01930422</nct_id>
  </id_info>
  <brief_title>Effect of Transcranial Direct Current Stimulation (tDCS) on Tobacco Consumption</brief_title>
  <acronym>TABELEC</acronym>
  <official_title>Effect of Transcranial Direct Current Stimulation (tDCS) on Tobacco Consumption.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Toulouse</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Toulouse</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of the protocol is to evaluate the effect of repeated application for 5
      consecutive days of a real tDCS compared to the application of a placebo tDCS (sham
      procedure) on the evolution of tobacco consumption in the short term between Day 1 and Day 5.

      The study hypothesis is that a repeated application for 5 consecutive days of a real tDCS on
      the left dorsolateral prefrontal cortex region will reduce the craving induced causing a
      decreased of daily tobacco consumption between Day 1 and Day 5 which can persist at the final
      visit between Day 15 and Day 20.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Smoking is a major public health problem and it is the leading cause of preventable death in
      the world. Care should include education, psychotherapy and treatments, but despite these
      therapeutics, the smoking cessation process is often characterized by relapses. The main risk
      factor for relapse is craving. Neurophysiological studies have provided evidence in the
      understanding of craving. This craving involves surface structures including the dorsolateral
      prefrontal cortex, accessible by neurostimulation. Repetitive neurostimulation applies on
      this structures involved in craving could therefore modulate it. Two non-invasive stimulation
      techniques exist: repetitive transcranial magnetic stimulation (rTMS) and transcranial direct
      current stimulation (tDCS). The choice of tDCS is based on its ease of use, excellent
      tolerance, its better quality of placebo and low cost.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2013</start_date>
  <completion_date type="Actual">February 2014</completion_date>
  <primary_completion_date type="Actual">February 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Relative change of individual salivary cotinine.</measure>
    <time_frame>Outcome measure is assessed at Day1 and Day5</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Relative change of individual salivary cotinine</measure>
    <time_frame>Outcome measure is assessed at Day5 and between Day15 and Day20.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Exhaled carbon monoxide.</measure>
    <time_frame>Outcome measure is assessed at day 0, day 1, day 2, day 3, day 4, day 5 and between day 15 and day 20.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of cigarettes smoked per day</measure>
    <time_frame>Outcome measure is assessed at day 0, day1, day2, day3, day4, day5 and between day 15 and 20</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Technical feasibility of outpatient</measure>
    <time_frame>Outcome measure is assessed between day 15 and 20.</time_frame>
    <description>The feasibility is assessed by the number of smokers following the entire protocol.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of craving</measure>
    <time_frame>Outcome measure is assessed at Day1, day2, day3, day4, day5 and betwenn day 15 to day 20.</time_frame>
    <description>Measurement of craving from Day1 to Day5 and at the final visits assessed by a VAS: visual analogue scale from 0 (no urge to smoke at all) to 10 (intense desire compelling smoking) and the questionnaire called the 12-item French Tobacco Craving Questionnaire (FCTQ-12).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">34</enrollment>
  <condition>Tobacco Use Disorder</condition>
  <arm_group>
    <arm_group_label>Real tDCS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Direct transcranial electrical stimulation (tDCS procedure)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo tDCS</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Sham procedure</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>tDCS procedure</intervention_name>
    <description>The tDCS is a non-invasive neuromodulation method. A stimulator delivers a constant current of low intensity (1-2 mA) applied to the average of two bipolar electrodes placed on the scalp for 20 minutes. This constant current generates a static electric field that selectively modulates the activity of cortical neurones. A tingling sensation under the electrodes appears at the beginning and at the end of stimulation but it is transient and disappears quickly in 30 or 60 seconds.</description>
    <arm_group_label>Real tDCS</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Sham procedure</intervention_name>
    <description>The tDCS placebo differs from the real tDCS by the interruption of stimulation after 30 to 60 seconds and reactivation of this stimulation 30 to 60 seconds before the end of the session, which lasted 20 minutes. The tingling felt at the beginning and the end of the session will be the same as those experienced with real stimulation. The electrodes establishment does not differ with respect to tDCS.</description>
    <arm_group_label>Placebo tDCS</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Aged 18 to 60 years old

          -  Smoking ≥ 5 years

          -  Smoking ≥ 15 manufactured cigarettes per day or ≥ 10 rolled cigarettes per day

          -  Fagerström test ≥ 5

          -  Smokers who have at least an attempt to stop of minimum 7 days

          -  Written informed consent signed by the patient

          -  Affiliated to medical insurance

        Exclusion Criteria:

          -  Co-addiction (cannabis, alcohol, other drugs)

          -  HAD test: D ≥ 8; A + D ≥ 19

          -  Treatment by nicotine replacement therapy, bupropion or varenicline within 30 days
             prior inclusion

          -  Neuropsychiatric disease, considered serious by the investigator

          -  Psychotropic treatment (antidepressant, anxiolytic, antipsychotic)

          -  Skin scalp dermatosis

          -  Pregnancy or breastfeeding. Positive pregnancy test.

          -  Patient under guardianship, trusteeship or judicial protection

          -  Patient in inclusion period for another clinical research protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rose-Marie ROUQUET, MD</last_name>
    <role>Principal Investigator</role>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital, Toulouse</name>
      <address>
        <city>Toulouse</city>
        <state>Midi-Pyrénées</state>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Organisation Mondiale de la Santé. Rapport de l'OMS sur l'épidémie mondiale de tabagisme 2011, résumé d'orientation. OMS 2011</citation>
  </reference>
  <reference>
    <citation>Rapport OMS Mpower 2008.</citation>
  </reference>
  <reference>
    <citation>Observatoire français des drogues et des toxicomanies. Les niveaux d'usage des drogues en France en 2010. OFDT Tendances, n°76, juin 2011</citation>
  </reference>
  <reference>
    <citation>Le Faou AL, Scemama O. [Epidemiology of tobacco smoking]. Rev Mal Respir. 2005 Dec;22(6 Pt 2):8S27-32. Review. French.</citation>
    <PMID>16340832</PMID>
  </reference>
  <reference>
    <citation>Hill C, Jougla E, Beck F. Le point sur l'épidémie de cancer du poumon dû au tabagisme. BEH mai 2010; 19-20: 210-213</citation>
  </reference>
  <reference>
    <citation>Fuxe, K., Anderson, K., Eneroth, P., 1987. Effects of nicotine and exposure to cigarette smoke on discrete dopamine and noradrenaline nerve terminal systems of the telcephalon and diencephalon of the rat: relationship to reward mechanisms and distribution of nicotine binding sites in brain. In: Martin, W.R., Van Loon, G.R., Iwamoto, E.T., et al. (Eds.), Tobacco Smoking and Nicotine: A Neurobiological Approach. Plenum, New York, pp. 225-262.</citation>
  </reference>
  <reference>
    <citation>Pert, A., Clarke, P.B.S., 1987. Nicotine modulation of dopaminergic transmission: functional implications. In: Martin, W.R., Van Loon, G.R., Iwamoto, E.T., et al. (Eds.), Tobacco, Smoking and Nicotine: A Neurobiological Approach. Plenum, New York, pp.169-189.</citation>
  </reference>
  <reference>
    <citation>United States Department of Health and Human Services, 1988. The Health Consequences of Smoking: Nicotine Addiction. US Government Printing Office, Washington, DC DHHS Publication No.CDC-88-8406.</citation>
  </reference>
  <reference>
    <citation>Clarke, P., 1990. Mesolimbic dopaminergic activation: the key to nicotine reinforcement. In: Bock, G., Marsh, J. (Eds.), The Biology of Nicotine Dependence. Wiley, New York, pp. 153-168.</citation>
  </reference>
  <reference>
    <citation>Pich EM, Pagliusi SR, Tessari M, Talabot-Ayer D, Hooft van Huijsduijnen R, Chiamulera C. Common neural substrates for the addictive properties of nicotine and cocaine. Science. 1997 Jan 3;275(5296):83-6.</citation>
    <PMID>8974398</PMID>
  </reference>
  <reference>
    <citation>Wise RA, Bozarth MA. A psychomotor stimulant theory of addiction. Psychol Rev. 1987 Oct;94(4):469-92. Review.</citation>
    <PMID>3317472</PMID>
  </reference>
  <reference>
    <citation>Collins AC, Marks MJ. Progress towards the development of animal models of smoking-related behaviors. J Addict Dis. 1991;10(1-2):109-26.</citation>
    <PMID>2065112</PMID>
  </reference>
  <reference>
    <citation>Pomerleau OF. Individual differences in sensitivity to nicotine: implications for genetic research on nicotine dependence. Behav Genet. 1995 Mar;25(2):161-77. Review.</citation>
    <PMID>7733857</PMID>
  </reference>
  <reference>
    <citation>Robinson TE, Berridge KC. The neural basis of drug craving: an incentive-sensitization theory of addiction. Brain Res Brain Res Rev. 1993 Sep-Dec;18(3):247-91. Review.</citation>
    <PMID>8401595</PMID>
  </reference>
  <reference>
    <citation>Heatherton TF, Kozlowski LT, Frecker RC, Fagerström KO. The Fagerström Test for Nicotine Dependence: a revision of the Fagerström Tolerance Questionnaire. Br J Addict. 1991 Sep;86(9):1119-27.</citation>
    <PMID>1932883</PMID>
  </reference>
  <reference>
    <citation>Pickens RW, Johanson CE. Craving: consensus of status and agenda for future research. Drug Alcohol Depend. 1992 Jun;30(2):127-31. Review.</citation>
    <PMID>1633752</PMID>
  </reference>
  <reference>
    <citation>Marlatt, G.A., Gordon, J.R. (Eds.), 1985. Relapse Prevention. Guilford, New York</citation>
  </reference>
  <reference>
    <citation>Killen JD, Fortmann SP. Craving is associated with smoking relapse: findings from three prospective studies. Exp Clin Psychopharmacol. 1997 May;5(2):137-42.</citation>
    <PMID>9234050</PMID>
  </reference>
  <reference>
    <citation>Shiffman S, Engberg JB, Paty JA, Perz WG, Gnys M, Kassel JD, Hickcox M. A day at a time: predicting smoking lapse from daily urge. J Abnorm Psychol. 1997 Feb;106(1):104-16.</citation>
    <PMID>9103722</PMID>
  </reference>
  <reference>
    <citation>Abrams DB, Monti PM, Pinto RP, Elder JP, Brown RA, Jacobus SI. Psychosocial stress and coping in smokers who relapse or quit. Health Psychol. 1987;6(4):289-303.</citation>
    <PMID>3301320</PMID>
  </reference>
  <reference>
    <citation>Niaura R, Abrams DB, Pedraza M, Monti PM, Rohsenow DJ. Smokers' reactions to interpersonal interaction and presentation of smoking cues. Addict Behav. 1992 Nov-Dec;17(6):557-66.</citation>
    <PMID>1488936</PMID>
  </reference>
  <reference>
    <citation>Shiffman S, Paty JA, Gnys M, Kassel JA, Hickcox M. First lapses to smoking: within-subjects analysis of real-time reports. J Consult Clin Psychol. 1996 Apr;64(2):366-79.</citation>
    <PMID>8871421</PMID>
  </reference>
  <reference>
    <citation>Brody AL, Mandelkern MA, London ED, Childress AR, Lee GS, Bota RG, Ho ML, Saxena S, Baxter LR Jr, Madsen D, Jarvik ME. Brain metabolic changes during cigarette craving. Arch Gen Psychiatry. 2002 Dec;59(12):1162-72.</citation>
    <PMID>12470133</PMID>
  </reference>
  <reference>
    <citation>McClernon FJ, Hiott FB, Huettel SA, Rose JE. Abstinence-induced changes in self-report craving correlate with event-related FMRI responses to smoking cues. Neuropsychopharmacology. 2005 Oct;30(10):1940-7.</citation>
    <PMID>15920499</PMID>
  </reference>
  <reference>
    <citation>Wilson SJ, Sayette MA, Delgado MR, Fiez JA. Instructed smoking expectancy modulates cue-elicited neural activity: a preliminary study. Nicotine Tob Res. 2005 Aug;7(4):637-45.</citation>
    <PMID>16085533</PMID>
  </reference>
  <reference>
    <citation>Smolka MN, Bühler M, Klein S, Zimmermann U, Mann K, Heinz A, Braus DF. Severity of nicotine dependence modulates cue-induced brain activity in regions involved in motor preparation and imagery. Psychopharmacology (Berl). 2006 Mar;184(3-4):577-88. Epub 2005 Aug 13.</citation>
    <PMID>16133128</PMID>
  </reference>
  <reference>
    <citation>Brody AL, Mandelkern MA, Olmstead RE, Jou J, Tiongson E, Allen V, Scheibal D, London ED, Monterosso JR, Tiffany ST, Korb A, Gan JJ, Cohen MS. Neural substrates of resisting craving during cigarette cue exposure. Biol Psychiatry. 2007 Sep 15;62(6):642-51. Epub 2007 Jan 9.</citation>
    <PMID>17217932</PMID>
  </reference>
  <reference>
    <citation>Lee JH, Lim Y, Wiederhold BK, Graham SJ. A functional magnetic resonance imaging (FMRI) study of cue-induced smoking craving in virtual environments. Appl Psychophysiol Biofeedback. 2005 Sep;30(3):195-204.</citation>
    <PMID>16167185</PMID>
  </reference>
  <reference>
    <citation>Due DL, Huettel SA, Hall WG, Rubin DC. Activation in mesolimbic and visuospatial neural circuits elicited by smoking cues: evidence from functional magnetic resonance imaging. Am J Psychiatry. 2002 Jun;159(6):954-60.</citation>
    <PMID>12042183</PMID>
  </reference>
  <reference>
    <citation>Ferguson SG, Shiffman S. The relevance and treatment of cue-induced cravings in tobacco dependence. J Subst Abuse Treat. 2009 Apr;36(3):235-43. doi: 10.1016/j.jsat.2008.06.005. Epub 2008 Aug 20. Review.</citation>
    <PMID>18715743</PMID>
  </reference>
  <reference>
    <citation>Tiffany ST, Cox LS, Elash CA. Effects of transdermal nicotine patches on abstinence-induced and cue-elicited craving in cigarette smokers. J Consult Clin Psychol. 2000 Apr;68(2):233-40.</citation>
    <PMID>10780123</PMID>
  </reference>
  <reference>
    <citation>Singleton EG, Anderson LM, Heishman SJ. Reliability and validity of the Tobacco Craving Questionnaire and validation of a craving-induction procedure using multiple measures of craving and mood. Addiction. 2003 Nov;98(11):1537-46.</citation>
    <PMID>14616180</PMID>
  </reference>
  <reference>
    <citation>Heishman SJ, Singleton EG, Moolchan ET. Tobacco Craving Questionnaire: reliability and validity of a new multifactorial instrument. Nicotine Tob Res. 2003 Oct;5(5):645-54.</citation>
    <PMID>14577981</PMID>
  </reference>
  <reference>
    <citation>Berlin I, Vorspan F, Singleton EG, Warot D, Notides C, Heishman SJ. Reliability and validity of the French version of the tobacco craving questionnaire. Eur Addict Res. 2005;11(2):62-8.</citation>
    <PMID>15785066</PMID>
  </reference>
  <reference>
    <citation>Heishman SJ, Singleton EG, Pickworth WB. Reliability and validity of a Short Form of the Tobacco Craving Questionnaire. Nicotine Tob Res. 2008 Apr;10(4):643-51. doi: 10.1080/14622200801908174.</citation>
    <PMID>18418787</PMID>
  </reference>
  <reference>
    <citation>Berlin I, Singleton EG, Heishman SJ. Validity of the 12-item French version of the Tobacco Craving Questionnaire in treatment-seeking smokers. Nicotine Tob Res. 2010 May;12(5):500-7. doi: 10.1093/ntr/ntq039. Epub 2010 Mar 24.</citation>
    <PMID>20335281</PMID>
  </reference>
  <reference>
    <citation>Koob GF, Sanna PP, Bloom FE. Neuroscience of addiction. Neuron. 1998 Sep;21(3):467-76. Review.</citation>
    <PMID>9768834</PMID>
  </reference>
  <reference>
    <citation>AFSSAPS. [Drug and non-drug strategies for smoking cessation. AFSSAPS guidelines]. Rev Pneumol Clin. 2003 Nov;59(5 Pt 1):291-5. French.</citation>
    <PMID>14707924</PMID>
  </reference>
  <reference>
    <citation>Stead LF, Perera R, Bullen C, Mant D, Lancaster T. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev. 2008 Jan 23;(1):CD000146. doi: 10.1002/14651858.CD000146.pub3. Review. Update in: Cochrane Database Syst Rev. 2012;11:CD000146.</citation>
    <PMID>18253970</PMID>
  </reference>
  <reference>
    <citation>Woolacott NF, Jones L, Forbes CA, Mather LC, Sowden AJ, Song FJ, Raftery JP, Aveyard PN, Hyde CJ, Barton PM. The clinical effectiveness and cost-effectiveness of bupropion and nicotine replacement therapy for smoking cessation: a systematic review and economic evaluation. Health Technol Assess. 2002;6(16):1-245. Review.</citation>
    <PMID>12269277</PMID>
  </reference>
  <reference>
    <citation>Silagy C, Lancaster T, Stead L, Mant D, Fowler G. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev. 2004;(3):CD000146. Review. Update in: Cochrane Database Syst Rev. 2008;(1):CD000146.</citation>
    <PMID>15266423</PMID>
  </reference>
  <reference>
    <citation>Hughes JR, Stead LF, Lancaster T. Antidepressants for smoking cessation. Cochrane Database Syst Rev. 2007 Jan 24;(1):CD000031. Review. Update in: Cochrane Database Syst Rev. 2014;1:CD000031.</citation>
    <PMID>17253443</PMID>
  </reference>
  <reference>
    <citation>Moore TJ, Furberg CD, Glenmullen J, Maltsberger JT, Singh S. Suicidal behavior and depression in smoking cessation treatments. PLoS One. 2011;6(11):e27016. doi: 10.1371/journal.pone.0027016. Epub 2011 Nov 2.</citation>
    <PMID>22073240</PMID>
  </reference>
  <reference>
    <citation>Cahill K, Stead LF, Lancaster T. Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst Rev. 2011 Feb 16;(2):CD006103. doi: 10.1002/14651858.CD006103.pub5. Review. Update in: Cochrane Database Syst Rev. 2012;4:CD006103.</citation>
    <PMID>21328282</PMID>
  </reference>
  <reference>
    <citation>Afssaps - Plan de gestion de risque de la spécialité pharmaceutique CHAMPIX ® Fev 2008</citation>
  </reference>
  <reference>
    <citation>Gourlay SG, Stead LF, Benowitz NL. Clonidine for smoking cessation. Cochrane Database Syst Rev. 2004;(3):CD000058. Review.</citation>
    <PMID>15266422</PMID>
  </reference>
  <reference>
    <citation>Public Health Service. Treating tobacco use and dependence. Clinical practice guideline. Washington (DC):US Department of Health and Human Services; 2000.</citation>
  </reference>
  <reference>
    <citation>Raupach T, Hoogsteder PH, Onno van Schayck CP. Nicotine vaccines to assist with smoking cessation: current status of research. Drugs. 2012 Mar 5;72(4):e1-16. doi: 10.2165/11599900-000000000-00000. Review.</citation>
    <PMID>22356293</PMID>
  </reference>
  <reference>
    <citation>Cottraux J. Les thérapies comportementales et cognitives, 4ème édition Historique Masson 2004; 2: 20-32</citation>
  </reference>
  <reference>
    <citation>Cottraux J. Les thérapies comportementales et cognitives, 4ème édition Des théories de l'apprentissage aux théories cognitives Masson 2004; 3: 35-66</citation>
  </reference>
  <reference>
    <citation>Le Foll B, Aubin HJ, Lagrue G. [Behavioral and cognitive therapy to break the smoking habit. Review of the literature]. Ann Med Interne (Paris). 2002 May;153(3 Suppl):1S32-40. French.</citation>
    <PMID>12218881</PMID>
  </reference>
  <reference>
    <citation>Avis de la HAS, Haute Autorité de Santé Stratégies thérapeutiques d'aide au sevrage tabagique, efficacité, efficience et prise en charge financière. HAS, octobre 2006</citation>
  </reference>
  <reference>
    <citation>Agence Française de Sécurité Sanitaire des Produits de Santé (AFSSAPS). [Drug and non-drug therapeutic strategies to favor smoking cessation. Practical therapeutic guide. Recommended good practices]. J Mal Vasc. 2003 Dec;28(5):287-91. French.</citation>
    <PMID>14978434</PMID>
  </reference>
  <reference>
    <citation>Lang N, Hasan A, Sueske E, Paulus W, Nitsche MA. Cortical hypoexcitability in chronic smokers? A transcranial magnetic stimulation study. Neuropsychopharmacology. 2008 Sep;33(10):2517-23. Epub 2007 Dec 5.</citation>
    <PMID>18059439</PMID>
  </reference>
  <reference>
    <citation>Brunelin J, Poulet E, Boeuve C, Zeroug-vial H, d'Amato T, Saoud M. [Efficacy of repetitive transcranial magnetic stimulation (rTMS) in major depression: a review]. Encephale. 2007 Mar-Apr;33(2):126-34. Review. French.</citation>
    <PMID>17675907</PMID>
  </reference>
  <reference>
    <citation>Meng Z, Liu S, Zheng Y, Phillips JS. Repetitive transcranial magnetic stimulation for tinnitus. Cochrane Database Syst Rev. 2011 Oct 5;(10):CD007946. doi: 10.1002/14651858.CD007946.pub2. Review.</citation>
    <PMID>21975776</PMID>
  </reference>
  <reference>
    <citation>Barr MS, Fitzgerald PB, Farzan F, George TP, Daskalakis ZJ. Transcranial magnetic stimulation to understand the pathophysiology and treatment of substance use disorders. Curr Drug Abuse Rev. 2008 Nov;1(3):328-39. Review.</citation>
    <PMID>19630729</PMID>
  </reference>
  <reference>
    <citation>Höppner J, Broese T, Wendler L, Berger C, Thome J. Repetitive transcranial magnetic stimulation (rTMS) for treatment of alcohol dependence. World J Biol Psychiatry. 2011 Sep;12 Suppl 1:57-62. doi: 10.3109/15622975.2011.598383.</citation>
    <PMID>21905997</PMID>
  </reference>
  <reference>
    <citation>Barth KS, Rydin-Gray S, Kose S, Borckardt JJ, O'Neil PM, Shaw D, Madan A, Budak A, George MS. Food cravings and the effects of left prefrontal repetitive transcranial magnetic stimulation using an improved sham condition. Front Psychiatry. 2011 Mar 14;2:9. doi: 10.3389/fpsyt.2011.00009. eCollection 2011.</citation>
    <PMID>21556279</PMID>
  </reference>
  <reference>
    <citation>Johann M, Wiegand R, Kharraz A, Bobbe G, Sommer G, Hajak G, Wodarz N, Eichhammer P. [Transcranial magnetic stimulation for nicotine dependence]. Psychiatr Prax. 2003 May;30 Suppl 2:S129-31. German.</citation>
    <PMID>14509058</PMID>
  </reference>
  <reference>
    <citation>Eichhammer P, Johann M, Kharraz A, Binder H, Pittrow D, Wodarz N, Hajak G. High-frequency repetitive transcranial magnetic stimulation decreases cigarette smoking. J Clin Psychiatry. 2003 Aug;64(8):951-3.</citation>
    <PMID>12927012</PMID>
  </reference>
  <reference>
    <citation>Amiaz R, Levy D, Vainiger D, Grunhaus L, Zangen A. Repeated high-frequency transcranial magnetic stimulation over the dorsolateral prefrontal cortex reduces cigarette craving and consumption. Addiction. 2009 Apr;104(4):653-60. doi: 10.1111/j.1360-0443.2008.02448.x. Epub 2009 Jan 12.</citation>
    <PMID>19183128</PMID>
  </reference>
  <reference>
    <citation>Rose JE, McClernon FJ, Froeliger B, Behm FM, Preud'homme X, Krystal AD. Repetitive transcranial magnetic stimulation of the superior frontal gyrus modulates craving for cigarettes. Biol Psychiatry. 2011 Oct 15;70(8):794-9. doi: 10.1016/j.biopsych.2011.05.031. Epub 2011 Jul 18.</citation>
    <PMID>21762878</PMID>
  </reference>
  <reference>
    <citation>Nitsche MA, Paulus W. Excitability changes induced in the human motor cortex by weak transcranial direct current stimulation. J Physiol. 2000 Sep 15;527 Pt 3:633-9.</citation>
    <PMID>10990547</PMID>
  </reference>
  <reference>
    <citation>Nitsche MA, Cohen LG, Wassermann EM, Priori A, Lang N, Antal A, Paulus W, Hummel F, Boggio PS, Fregni F, Pascual-Leone A. Transcranial direct current stimulation: State of the art 2008. Brain Stimul. 2008 Jul;1(3):206-23. doi: 10.1016/j.brs.2008.06.004. Epub 2008 Jul 1. Review.</citation>
    <PMID>20633386</PMID>
  </reference>
  <reference>
    <citation>Gartside IB. Mechanisms of sustained increases of firing rate of neurones in the rat cerebral cortex after polarization: role of protein synthesis. Nature. 1968 Oct 26;220(5165):383-4.</citation>
    <PMID>4300961</PMID>
  </reference>
  <reference>
    <citation>Hattori Y, Moriwaki A, Hori Y. Biphasic effects of polarizing current on adenosine-sensitive generation of cyclic AMP in rat cerebral cortex. Neurosci Lett. 1990 Aug 24;116(3):320-4.</citation>
    <PMID>2173816</PMID>
  </reference>
  <reference>
    <citation>Islam N, Aftabuddin M, Moriwaki A, Hattori Y, Hori Y. Increase in the calcium level following anodal polarization in the rat brain. Brain Res. 1995 Jul 3;684(2):206-8.</citation>
    <PMID>7583224</PMID>
  </reference>
  <reference>
    <citation>Gandiga PC, Hummel FC, Cohen LG. Transcranial DC stimulation (tDCS): a tool for double-blind sham-controlled clinical studies in brain stimulation. Clin Neurophysiol. 2006 Apr;117(4):845-50. Epub 2006 Jan 19.</citation>
    <PMID>16427357</PMID>
  </reference>
  <reference>
    <citation>Bikson M, Datta A, Elwassif M. Establishing safety limits for transcranial direct current stimulation. Clin Neurophysiol. 2009 Jun;120(6):1033-4. doi: 10.1016/j.clinph.2009.03.018. Epub 2009 Apr 24.</citation>
    <PMID>19394269</PMID>
  </reference>
  <reference>
    <citation>Poreisz C, Boros K, Antal A, Paulus W. Safety aspects of transcranial direct current stimulation concerning healthy subjects and patients. Brain Res Bull. 2007 May 30;72(4-6):208-14. Epub 2007 Jan 24.</citation>
    <PMID>17452283</PMID>
  </reference>
  <reference>
    <citation>Fregni F, Liguori P, Fecteau S, Nitsche MA, Pascual-Leone A, Boggio PS. Cortical stimulation of the prefrontal cortex with transcranial direct current stimulation reduces cue-provoked smoking craving: a randomized, sham-controlled study. J Clin Psychiatry. 2008 Jan;69(1):32-40.</citation>
    <PMID>18312035</PMID>
  </reference>
  <reference>
    <citation>Boggio PS, Liguori P, Sultani N, Rezende L, Fecteau S, Fregni F. Cumulative priming effects of cortical stimulation on smoking cue-induced craving. Neurosci Lett. 2009 Sep 29;463(1):82-6. doi: 10.1016/j.neulet.2009.07.041. Epub 2009 Jul 18.</citation>
    <PMID>19619607</PMID>
  </reference>
  <reference>
    <citation>Boggio PS, Zaghi S, Villani AB, Fecteau S, Pascual-Leone A, Fregni F. Modulation of risk-taking in marijuana users by transcranial direct current stimulation (tDCS) of the dorsolateral prefrontal cortex (DLPFC). Drug Alcohol Depend. 2010 Dec 1;112(3):220-5. doi: 10.1016/j.drugalcdep.2010.06.019. Epub 2010 Aug 21.</citation>
    <PMID>20729009</PMID>
  </reference>
  <reference>
    <citation>Boggio PS, Sultani N, Fecteau S, Merabet L, Mecca T, Pascual-Leone A, Basaglia A, Fregni F. Prefrontal cortex modulation using transcranial DC stimulation reduces alcohol craving: a double-blind, sham-controlled study. Drug Alcohol Depend. 2008 Jan 1;92(1-3):55-60. Epub 2007 Jul 19.</citation>
    <PMID>17640830</PMID>
  </reference>
  <reference>
    <citation>Fu M, Fernandez E, Martínez-Sánchez JM, Pascual JA, Schiaffino A, Agudo A, Ariza C, Borràs JM, Samet JM; DCOT Study investigators. Salivary cotinine concentrations in daily smokers in Barcelona, Spain: a cross-sectional study. BMC Public Health. 2009 Sep 3;9:320. doi: 10.1186/1471-2458-9-320.</citation>
    <PMID>19728886</PMID>
  </reference>
  <reference>
    <citation>Fu M, Martínez-Sánchez JM, Agudo A, Pascual JA, Ariza C, Moncada A, Fernández E; DCOT Study Investigators. Nicotine depedence and salivary cotinine concentration in daily smokers. Eur J Cancer Prev. 2012 Jan;21(1):96-102. doi: 10.1097/CEJ.0b013e32834a7e59.</citation>
    <PMID>22129659</PMID>
  </reference>
  <verification_date>February 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 20, 2013</study_first_submitted>
  <study_first_submitted_qc>August 23, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 29, 2013</study_first_posted>
  <last_update_submitted>February 21, 2014</last_update_submitted>
  <last_update_submitted_qc>February 21, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 24, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Direct transcranial electrical stimulation (tDCS)</keyword>
  <keyword>Sham procedure</keyword>
  <keyword>Tobacco consumption</keyword>
  <keyword>Craving</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tobacco Use Disorder</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

